Literature DB >> 15352988

Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.

Michael R Bishop1, Seth M Steinberg, Ronald E Gress, Nancy M Hardy, Donna Marchigiani, Claude Kasten-Sportes, Robert Dean, Steven Z Pavletic, Juan Gea-Banacloche, Kathleen Castro, Fran Hakim, Michael Krumlauf, Elizabeth J Read, Charles Carter, Susan F Leitman, Daniel H Fowler.   

Abstract

Mixed chimaerism and graft rejection are higher after reduced-intensity allogeneic stem cell transplantation (RIST) with T-cell depleted (TCD) allografts. As host immune status before RIST affects engraftment, we hypothesized that targeted depletion of host lymphocytes prior to RIST would abrogate graft rejection and promote donor chimaerism. Lymphocyte-depleting chemotherapy was administered at conventional doses to subjects prior to RIST with the intent of decreasing CD4(+) counts to <0.05 x 10(9)cells/l. Subjects (n = 18) then received reduced-intensity conditioning followed by ex vivo TCD human leucocyte antigen-matched sibling allografts. All evaluable patients (n = 17) were engrafted; there were no late graft failures. At day +28 post-RIST, 12 patients showed complete donor chimaerism. Mixed chimaerism in the remaining five patients was associated with higher numbers of circulating host CD3(+) cells (P = 0.0032) after lymphocyte-depleting chemotherapy and was preferentially observed in T lymphoid rather than myeloid cells. Full donor chimaerism was achieved in all patients after planned donor lymphocyte infusions. These data reflect the importance of host immune status prior to RIST and suggest that targeted host lymphocyte depletion facilitates the engraftment of TCD allografts. Targeted lymphocyte depletion may permit an individualized approach to conditioning based on host immune status prior to RIST.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352988     DOI: 10.1111/j.1365-2141.2004.05133.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Authors:  Rajat Singh; Yujian Zhang; Ira Pastan; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

2.  Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.

Authors:  Rachel B Salit; Daniel H Fowler; Wyndham H Wilson; Robert M Dean; Steven Z Pavletic; Kieron Dunleavy; Frances Hakim; Terry J Fry; Seth M Steinberg; Thomas E Hughes; Jeanne Odom; Kelly Bryant; Ronald E Gress; Michael R Bishop
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

3.  Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.

Authors:  Nancy M Hardy; Miriam E Mossoba; Seth M Steinberg; Vicki Fellowes; Xiao-Yi Yan; Frances T Hakim; Rebecca R Babb; Daniele Avila; Juan Gea-Banacloche; Claude Sportès; Bruce L Levine; Carl H June; Hahn M Khuu; Ashley E Carpenter; Michael C Krumlauf; Andrew J Dwyer; Ronald E Gress; Daniel H Fowler; Michael R Bishop
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

4.  Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

Authors:  Nirali N Shah; Kristin Baird; Cynthia P Delbrook; Thomas A Fleisher; Mark E Kohler; Shakuntala Rampertaap; Kimberly Lemberg; Carolyn K Hurley; David E Kleiner; Melinda S Merchant; Stefania Pittaluga; Marianna Sabatino; David F Stroncek; Alan S Wayne; Hua Zhang; Terry J Fry; Crystal L Mackall
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

5.  Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.

Authors:  Kristin Baird; Terry J Fry; Seth M Steinberg; Michael R Bishop; Daniel H Fowler; Cynthia P Delbrook; Jennifer L Humphrey; Alison Rager; Kelly Richards; Alan S Wayne; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-05       Impact factor: 5.742

6.  Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.

Authors:  Brian C Shaffer; Marko Modric; Maryalice Stetler-Stevenson; Diane C Arthur; Seth M Steinberg; David J Liewehr; Daniel H Fowler; Robert P Gale; Michael R Bishop; Steven Z Pavletic
Journal:  Exp Hematol       Date:  2013-05-18       Impact factor: 3.084

Review 7.  Prophylaxis of acute GVHD: manipulate the graft or the environment?

Authors:  A John Barrett; Katarina Le Blanc
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

8.  Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.

Authors:  Nancy M Hardy; Frances Hakim; Seth M Steinberg; Michael Krumlauf; Romana Cvitkovic; Rebecca Babb; Jeanne Odom; Daniel H Fowler; Ronald E Gress; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-16       Impact factor: 5.742

9.  Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.

Authors:  Rachel B Salit; Daniel H Fowler; Robert M Dean; Steven Z Pavletic; Frances T Hakim; Seth M Steinberg; Nancy T Hardy; Claude Sportes; Ronald E Gress; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2013-08-13       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.